Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Invictus BioPharma
Sydney, New South Wales, Australiavgiht.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Invictus BioPharma developed a platform for transmucosal delivery of tocotrienols. As of early 2022, two drug candidates were commencing Phase II clinical trials targeting NAFLD/NASH and pancreatic cancer. Two additional prodrug candidates were in preclinical optimization with Monash Institute collaborations.
- Therapeutic areas
- GastroenterologyOncology
- Modalities
- Small molecules (tocotrienols and tocotrienol prodrugs)Nutraceuticals
- Industry
- Biotech
02
Partnerships
Collaboration with Professor Christopher Porter’s group at Monash Institute of Pharmaceutical Sciences for research optimization
Beyond the preview
Go deeper on Invictus BioPharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Invictus BioPharma.